Clinical trial
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
NCT02874807 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
- Lead sponsor
- University Hospital, Basel, Switzerland
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 5, 2016
- Completion date
- January 14, 2019
- Enrollment
- 88 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
siadh